Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.43 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.43 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.43 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.43 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160106 | 0.86 | DGAT1 (0.50) | DGAT1PLA2G10PLA2G2APLA2G1BPLA2G5 | |
| SCHEMBL23655507 | 0.80 | HDAC1 (0.40) | LMNA | |
| SCHEMBL10211142 | 0.77 | DGAT1 (0.55) | DGAT1PARP10PARP15LMNAHTT | |
| SCHEMBL14032611 | 0.76 | PLA2G10 (0.46) | PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C | |
| SCHEMBL25152138 | 0.75 | OPRM1 (0.47) | DGAT1PARP10PARP15LMNAHTT | |
| SCHEMBL29162430 | 0.75 | OPRM1 (0.47) | DGAT1PARP10PARP15LMNAHTT | |
| SCHEMBL31413134 | 0.75 | DGAT1 (0.56) | DGAT1PARP10PARP15LMNAHTT | |
| SCHEMBL15729805 | 0.75 | DGAT1 (0.56) | DGAT1PARP10PARP15LMNAHTT | |
| SCHEMBL6370206 | 0.75 | DGAT1 (0.49) | DGAT1PLA2G10PLA2G2APARP10PARP15 | |
| SCHEMBL6365253 | 0.75 | TRPV4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-6265581-B1 | REACTING SPECIFIED EPOXIDE AND AMINE, REACTING PRODUCT WITH ACID TO FORM ACID ADDITION SALT | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6093735-A | TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | DGAT1 1005/4885PLA2G10 3450/4885PLA2G2A 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.